Vigabatrin

氨己烯酸

Report date: 2025/12/30 16:02:48
NME

Base Information

Drug NameVigabatrin
Drug Alias Name氨乙烯酸VigabatrineVigabatrinumGamma-vinyl-GABAVigabatrina +[17] 
ClassificationSmall molecules
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsCocaine-Related DisordersAlcoholismSubstance-Related Disorders +[16] 
Global Approved IndicationsSeizuresSpasms, InfantileEpilepsy, Complex Partial +[4] 
Approved Indications in ChinaSpasms, InfantileEpilepsies, Partial
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1989/09/22
Country/TerritoryUnited StatesUnited KingdomEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesLundbeck Pharms LlcWashington University School Of MedicineOrphelia Pharma +[7] 
Inactive CompaniesThe University Of ArizonaNational Institute On Drug AbuseCatalyst Pharmaceuticals Inc +[5] 
Active IndicationsObesityStatus EpilepticusSeizures +[9] 
Inactive IndicationsCocaine-Related DisordersAlcoholismSubstance-Related Disorders +[7] 

Other Information

ATC CodeN03AG04
Related LinksWikipediaDrugBankKEGG